Reactions 1495, p8 - 5 Apr 2014

Antineoplastics

Stomatitis and mucositis in an elderly patient: casereport

A 67-year-old man developed stomatitis while receivingfluorouracil, folinic acid [leucovorin] and oxaliplatin (FOLFOX)for metastatic colorectal cancer. He then developed mucositisduring treatment with cetuximab [routes, durations oftreatment to reactions onset and outcomes not stated; not alldosages stated].

The man, who had been diagnosed with colorectal cancer in2008, was diagnosed with metastatic disease in April 2011. Hebegan receiving FOLFOX, consisting of a fluorouracil200 mg/m2 bolus and 1200 mg/m2 continuous infusion over48h, folinic acid and oxaliplatin 75 mg/m2 every 2 weeks.During treatment, he developed grade 2 stomatitis. Afterreceiving a total of 21 cycles of FOLFOX, he was switched tocetuximab. He received a 400 mg/m2 loading dose followed by250 mg/m2 weekly. He subsequently developed grade 2mucositis. At last follow-up, he continued to receivecetuximab.

Author comment: "The patient tolerated his [FOLFOX]treatment very well, with only grade 2 stomatitis as asignificant toxicity. . . He tolerated this [cetuximab] treatmentvery well, with only grade 2 mucositis."Elsoueidi R, et al. Safety and efficacy of FOLFOX followed by cetuximab formetastatic colorectal cancer with severe liver dysfunction. Journal of the NationalComprehensive Cancer Network 12: 155-160, No. 2, Feb 2014 - USA 803101133

1

Reactions 5 Apr 2014 No. 14950114-9954/14/1495-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved